Literature DB >> 10531272

A new rat model of otitis media caused by Streptococcus pneumoniae: conditions and application in immunization protocols.

L T van der Ven1, G P van den Dobbelsteen, B Nagarajah, H van Dijken, P M Dortant, J G Vos, P J Roholl.   

Abstract

Streptococcus pneumoniae (pneumococcus [Pn]) can be cultured from up to 50% of acute otitis media (AOM) effusions, and these bacteria are the most common cause of AOM-related complications. With the recent advent of antibiotic-resistant Pn strains, treatment of Pn infections may meet with serious difficulties. Prevention through vaccination, notably for the four most common occurring Pn serotypes in humans (i.e., Pn 6B, Pn 14, Pn 19F, and Pn 23F), is a helpful alternative. Testing of vaccine efficacy should occur in an appropriate animal AOM model, which is presented here. The four involved Pn serotypes are not pathogenic to the rat, which was chosen as the experimental animal for practical reasons. To induce a natural infection (i.e., ascending through the eustachian tube), the mucociliary clearance of the eustachian tube was impaired by infusing histamine into the tympanic cavity on 2 consecutive days before intranasal inoculation of the bacteria. With this simple protocol, high and reproducible infection rates, as determined with bacterial cultures, of Pn-induced AOM (approximately 70%) with the two major Pn serotypes 14 and 19F (Pn 14 and Pn 19F) were obtained, whereas lower infection rates (25 to 50%) with Pn 6B and Pn 23F were obtained. In this model, intranasal priming with pneumococci, as well as subcutaneous vaccination with Pn 14 tetanus toxoid-conjugated polysaccharide, induced a protective effect against the induction of otitis media with these bacteria. This shows that immunity to Pn 14 AOM can be induced by both mucosal and systemic presentations of antigen. In conclusion, we have developed an animal model for Pn-induced AOM, which is suitable for the evaluation of the protecting effect of immunization.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10531272      PMCID: PMC96998     

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  24 in total

1.  Pneumococcal bacteremia during oral treatment with cefixime for otitis media.

Authors:  M G Ottolini; D P Ascher; T J Cieslak; S Modica-Lucero
Journal:  Pediatr Infect Dis J       Date:  1991-06       Impact factor: 2.129

2.  The role of microorganisms in experimental eustachian tube obstruction.

Authors:  W Kuijpers; J M van der Beek
Journal:  Acta Otolaryngol Suppl       Date:  1984

3.  Clinical-histopathological correlations in experimental otitis media: implications for silent otitis media in humans.

Authors:  G S Giebink; M L Ripley; D A Shea; P F Wright; M M Paparella
Journal:  Pediatr Res       Date:  1985-04       Impact factor: 3.756

4.  Detection of IgA antibodies and quantification of IgA antibody-producing cells specific for ovalbumin or Trichinella spiralis in the rat.

Authors:  H Van Loveren; A D Osterhaus; J Nagel; H J Schuurman; J G Vos
Journal:  Scand J Immunol       Date:  1988-09       Impact factor: 3.487

5.  The pathogenesis of pneumococcal otitis media in chinchillas and the efficacy of vaccination in prophylaxis.

Authors:  G S Giebink
Journal:  Rev Infect Dis       Date:  1981 Mar-Apr

6.  Histamine-induced mucociliary dysfunction and otitis media with effusion.

Authors:  Y Esaki; Y Ohashi; H Furuya; Y Sugiura; Y Ohno; H Okamoto; Y Nakai
Journal:  Acta Otolaryngol Suppl       Date:  1991

7.  Immunogenicity of Streptococcus pneumoniae type 6B and 14 polysaccharide-tetanus toxoid conjugates and the effect of uncoupled polysaccharide on the antigen-specific immune response.

Authors:  M E Rodriguez; G P van den Dobbelsteen; L A Oomen; O de Weers; L van Buren; M Beurret; J T Poolman; P Hoogerhout
Journal:  Vaccine       Date:  1998-12       Impact factor: 3.641

Review 8.  Pneumococcal polysaccharide vaccines: indications, efficacy and recommendations.

Authors:  G A Bruyn; R van Furth
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-11       Impact factor: 3.267

9.  A rat model for pneumococcal otitis media.

Authors:  A Hermansson; P Emgård; K Prellner; S Hellström
Journal:  Am J Otolaryngol       Date:  1988 May-Jun       Impact factor: 1.808

10.  Effects of various inflammatory mediators on eustachian tube patency.

Authors:  T Minami; N Kubo; K Tomoda; T Kumazawa
Journal:  Acta Otolaryngol       Date:  1992       Impact factor: 1.494

View more
  6 in total

1.  Heparin binding-epidermal growth factor-like growth factor for the regeneration of chronic tympanic membrane perforations in mice.

Authors:  Peter Luke Santa Maria; Sungwoo Kim; Yasin Kursad Varsak; Yunzhi Peter Yang
Journal:  Tissue Eng Part A       Date:  2015-03-17       Impact factor: 3.845

2.  Novel method for non-invasive induction of a middle-ear biofilm in the rat.

Authors:  Eric J Chaney; Cac T Nguyen; Stephen A Boppart
Journal:  Vaccine       Date:  2011-01-04       Impact factor: 3.641

Review 3.  Animal models of Streptococcus pneumoniae disease.

Authors:  Damiana Chiavolini; Gianni Pozzi; Susanna Ricci
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

4.  Molecular characterization of pneumococcal isolates from pets and laboratory animals.

Authors:  Mark van der Linden; Adnan Al-Lahham; Werner Nicklas; Ralf René Reinert
Journal:  PLoS One       Date:  2009-12-14       Impact factor: 3.240

5.  Intranasal immunization with pneumococcal conjugate vaccines with LT-K63, a nontoxic mutant of heat-Labile enterotoxin, as adjuvant rapidly induces protective immunity against lethal pneumococcal infections in neonatal mice.

Authors:  Håvard Jakobsen; Stefania Bjarnarson; Giuseppe Del Giudice; Monique Moreau; Claire-Anne Siegrist; Ingileif Jonsdottir
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

6.  Histology of sheep temporal bone.

Authors:  Hormy Biavatti Soares; Luiz Lavinsky
Journal:  Braz J Otorhinolaryngol       Date:  2011-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.